Clostridium leptum group bacteria abundance and diversity in the fecal microbiota of patients with inflammatory bowel disease: a case–control study in India

BMC Gastroenterology

Balakrishnan S Ramakrishna¹  Srinivasan Pugazhendhi¹  Vijayalakshmi Sankaran¹  Jayakanthan Kabeerdoss¹ 

[1] The Wellcome Trust Research Laboratory, Department of Gastrointestinal Sciences, Christian Medical College, Vellore, 632004, India

关键词: Short chain fatty acids;    Ulcerative colitis;    Crohn’s disease;    Dysbiosis;    Clostridial cluster IV;   

Others  :  858207
DOI  :  10.1186/1471-230X-13-20

 received in 2012-08-15, accepted in 2013-01-23,  发布年份 2013

【 摘 要 】

Background

Alterations in the fecal bacterial flora occur in inflammatory bowel disease (IBD). We examined the abundance and diversity of Clostridium leptum group, an important group of carbohydrate-fermenting bacteria, in the feces of patients with IBD and compared them with healthy controls.

Methods

Seventeen healthy controls (HC), 20 patients with Crohn’s disease (CD) and 22 patients with ulcerative colitis (UC) participated in the study. DNA extracted from fecal samples was amplified by PCR targeting 16S rRNA gene sequences specific to C. leptum group. The PCR product was subjected to temporal temperature gradient electrophoresis (TTGE) and the number and position of individual bands were noted and diversity was estimated. The identity of bands at different positions was confirmed by cloning and sequencing. Real time quantitative PCR with Mesa Green, targeted at specific 16S rRNA gene sequences, was used to quantitate C. leptum group and its most prominent constituent, Faecalibacterium prausnitzii.

Results

Twenty five different operational taxonomic units (OTUs, equivalent to species) were identified constituting the C. leptum group in these participants. Their sequences were deposited in GenBank [accession numbers GQ465348 to GQ465370]. OTU number was significantly reduced in CD (7.7±3.7, mean±SD) and UC (9.0±3.0) compared to HC (11.9±2.2) (P=0.0005). The Simpson D index of alpha diversity was not significantly different between the three groups. Total numbers of C. leptum group bacteria and F. prausnitzii were reduced in both CD and UC compared to HC (P=0.0036 and P<0.0001 respectively). Disease activity did not influence numbers of C. leptum or F. prausnitzii in patients with CD or UC.

Conclusion

C. leptum numbers and diversity were significantly reduced in both CD and UC suggesting that alterations noted were not specific to one disease. This could contribute to reduced short chain fatty acid production in IBD.

【 授权许可】

   
2013 Kabeerdoss et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Sghir A, Gramet G, Suau A, Rochet V, Pochart P, Dore J: Quantification of bacterial groups within human fecal flora by oligonucleotide probe hybridization. Appl Environ Microbiol 2000, 66:2263-6.
• [2]Lay C, Rigottier-Gois L, Holmstrøm K, Rajilic M, Vaughan EE, de Vos WM, Collins MD, Thiel R, Namsolleck P, Blaut M, Doré J: Colonic microbiota signatures across five northern European countries. Appl Environ Microbiol 2005, 71:4153-5.
• [3]Collins MD, Lawson PA, Willems A, Cordoba JJ, Fernandez-Garayzabal J, Garcia P, Cai J, Hippe H, Farrow JA: The phylogeny of the genus Clostridium: proposal of five new genera and eleven new species combinations. Int J Syst Bacteriol 1994, 44:812-26.
• [4]Louis P, Flint HJ: Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett 2009, 294:1-8.
• [5]Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottière HM, Doré J, Marteau P, Seksik P, Langella P: Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008, 105:16731-6.
• [6]Sartor RB: Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004, 126:1620-33.
• [7]Cucchiara S, Iebba V, Conte MP, Schippa S: The microbiota in inflammatory bowel disease in different age groups. Dig Dis 2009, 27:252-8.
• [8]Swidsinski A, Loening-Baucke V, Vaneechoutte M, Doerffel Y: Active Crohn’s disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora. Inflamm Bowel Dis 2008, 14:147-61.
• [9]Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, Cosnes J, Corthier G, Marteau P, Doré J: Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 2009, 15:1183-9.
• [10]Schwiertz A, Jacobi M, Frick JS, Richter M, Rusch K, Köhler H: Microbiota in pediatric inflammatory bowel disease. J Pediatr 2010, 157:240-244.
• [11]Mondot S, Kang S, Furet JP, Aguirre de Carcer D, McSweeney C, Morrison M, Marteau P, Doré J, Leclerc M: Highlighting new phylogenetic specificities of Crohn’s disease microbiota. Inflamm Bowel Dis 2011, 17:185-92.
• [12]Kang S, Denman SE, Morrison M, Yu Z, Dore J, Leclerc M, McSweeney CS: Dysbiosis of fecal microbiota in Crohn’s disease patients as revealed by a custom phylogenetic microarray. Inflamm Bowel Dis 2010, 16:2034-42.
• [13]Joossens M, Huys G, Cnockaert M, De Preter V, Verbeke K, Rutgeerts P, Vandamme P, Vermeire S: Dysbiosis of the faecal microbiota in patients with Crohn’s disease and their unaffected relatives. Gut 2011, 60:631-7.
• [14]Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R, Jarrin C, Chardon P, Marteau P, Roca J, Dore J: Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut 2006, 55:205-11.
• [15]Ouyang Q, Tandon R, Goh KL, Pan GZ, Fock KM, Fiocchi C, Lam SK, Xiao SD: Management consensus of inflammatory bowel disease for the Asia-Pacific region. J Gastroenterol Hepatol 2006, 21:1772-1782.
• [16]Best WR, Becktel JM, Singleton JW, Kern F Jr: Development of a Crohn’s disease activity index (National Cooperative Crohn’s Disease Study). Gastroenterology 1976, 70:439-44.
• [17]Truelove SC, Witts LJ: Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955, 2:1041-8.
• [18]Shen J, Zhang B, Wei G, Pang X, Wei H, Li M, Zhang Y, Jia W, Zhao L: Molecular profiling of the Clostridium leptum group in human fecal microflora by PCR-denaturing gradient gel electrophoresis and clone library analysis. Appl Environ Microbiol 2006, 72:5232-8.
• [19]Lay C, Sutren M, Rochet V, Saunier K, Doré J, Rigottier-Gois L: Design and validation of 16S rRNA probes to enumerate members of the Clostridium leptum subgroup in human faecal microbiota. Environ Microbiol 2005, 7:933-46.
• [20]Lay C, Dore J, Rigottier-Gois L: Separation of bacteria of the Clostridium leptum group from the human colonic microbiota by fluorescence-activated cell sorting or group-specific PCR using 16S rRNA gene oligonucleotides. FEMS Microbiol Ecol 2007, 60:513-20.
• [21]Sokol H, Seksik P, Rigottier-Gois L, Lay C, Lepage P, Podglajen I, Marteau P, Doré J: Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis 2006, 12:106-11.
• [22]Matsuki T, Watanabe K, Fujimoto J, Takada T, Tanaka R: Use of 16S rRNA gene-targeted group-specific primers for real-time PCR analysis of predominant bacteria in human feces. Appl Environ Microbiol 2004, 70:7220-8.
• [23]Scheppach W, Weiler F: The butyrate story: old wine in new bottles? Curr Opin Clin Nutr Metab Care 2004, 7:563-7.
• [24]Ramirez-Farias C, Slezak K, Fuller Z, Duncan A, Holtrop G, Louis P: Effect of inulin on the human gut microbiota: stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii. Br J Nutr 2009, 101:541-50.
• [25]Van Immerseel F, Ducatelle R, De Vos M, Boon N, Van De Wiele T, Verbeke K, Rutgeerts P, Sas B, Louis P, Flint HJ: Butyric acid-producing anaerobic bacteria as a novel probiotic treatment approach for inflammatory bowel disease. J Med Microbiol 2010, 59:141-3.